Company · RARE
Ultragenyx Pharmaceutical Inc.
Nasdaq's symbol directory lists RARE on Nasdaq as “Ultragenyx Pharmaceutical Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders sold on 7 occasions ($542K); 1 planned-sale notice; 9 filings by holders of 5% or more; 3 congressional trade disclosures; 5 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Horn Howard, Chief Financial Officer sold $381K
- Parschauer Karah Herdman, EVP and Chief Legal Officer sold $94K
- Sanders Corazon (Corsee) D. sold $50K
- Huizenga Theodore Alan, SVP, Chief Accounting Officer sold $17K
Every trade (7)
- SELLHorn Howard, Chief Financial Officer sold $108K
- SELLHuizenga Theodore Alan, SVP, Chief Accounting Officer sold $17K
- SELLHorn Howard, Chief Financial Officer sold $117K
- SELLParschauer Karah Herdman, EVP and Chief Legal Officer sold $47K
- SELLHorn Howard, Chief Financial Officer sold $156K
- SELLSanders Corazon (Corsee) D. sold $50K
- SELLParschauer Karah Herdman, EVP and Chief Legal Officer sold $47K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- THEODORE HUIZENGA $17K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- AQR Capital Management, LLC 0.64%
- STATE STREET CORPORATION 7.6%
- Vanguard Portfolio Management 8.6%
- Madison Avenue International LP 6.4%
- RTW Investments, LP 7.9%
- AQR Capital Management, LLC 6.66%
- STATE STREET CORPORATION 6.3%
- VANGUARD PORTFOLIO MANAGEMENT LLC 6.95%
- Vanguard Capital Management 5.13%
Congress · STOCK Act
The Althing
Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.
- Gilbert Cisneros (D-CA31): Purchase $1,001 - $15,000
- Gilbert Cisneros (D-CA31): Purchase $1,001 - $15,000
- Gilbert Cisneros (D-CA31): Purchase $1,001 - $15,000
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Completion of acquisition or disposition of assets; Results of operations and financial condition; Costs associated with exit or disposal activities Nov 3, 2026
- Other events Oct 19, 2026
- Entry into a material definitive agreement Oct 14, 2026
- Entry into a material definitive agreement Oct 7, 2026
- Other events Sep 17, 2026
Lobbying · Senate LDA reports
Lobbying filed
4 quarterly lobbying reports for 2026 naming Ultragenyx Pharmaceutical Inc. as the client: 1 filed by the company itself, 3 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.
- The company itself $440K
- MEHLMAN CONSULTING, INC. $60K
- MILLER STRATEGIES, LLC no amount stated
- MILLER STRATEGIES, LLC no amount stated
Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.